Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

130.55
+1.110.86%
Post-market: 130.55-0.0290-0.02%19:48 EDT
Volume:1.68M
Turnover:219.39M
Market Cap:19.13B
PE:12.91
High:131.13
Open:129.04
Low:128.82
Close:129.44
Loading ...

Drugmakers Down Premarket After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
08 Apr

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
05 Apr

Biogen Cut to Hold From Buy by Argus Research

Dow Jones
·
04 Apr

Biogen cut to Hold at Argus on expected earnings decline

TIPRANKS
·
04 Apr

Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs

THOMSON REUTERS
·
04 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Oil companies, US big banks, fintechs

Reuters
·
04 Apr

Argus Downgrades Biogen to Hold From Buy

MT Newswires Live
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

Biogen downgraded to Hold from Buy at Argus

TIPRANKS
·
04 Apr

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement

Simply Wall St.
·
04 Apr

Biogen : RBC Cuts Target Price to $221 From $225

THOMSON REUTERS
·
03 Apr

RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biopharma Credit Plc - Receives $8.25 Million Settlement Payment From Biogen

THOMSON REUTERS
·
02 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation

MT Newswires Live
·
02 Apr

BRIEF-Biogen’S Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation For The Treatment Of Alzheimer’S Disease

Reuters
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
02 Apr

Biogen: Phase 2 Celia Study Is NOW Fully Enrolled, With a Data Readout Expected in 2026

THOMSON REUTERS
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

GlobeNewswire
·
02 Apr